Elizabeth Garrett-Mayer to Cyclophosphamide
This is a "connection" page, showing publications Elizabeth Garrett-Mayer has written about Cyclophosphamide.
Connection Strength
0.156
-
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009 Jan; 58(1):49-59.
Score: 0.071
-
A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer. Cancer Immunol Res. 2014 Oct; 2(10):949-61.
Score: 0.027
-
Evaluation of a 15-week CHOP protocol for the treatment of canine multicentric lymphoma. Vet Comp Oncol. 2013 Dec; 11(4):306-15.
Score: 0.023
-
Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer. J Clin Oncol. 2009 Jun 10; 27(17):2816-22.
Score: 0.019
-
Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia. Clin Cancer Res. 2005 Dec 01; 11(23):8413-7.
Score: 0.015